Epidemiologic studies and novel clinical research approaches that impact TB vaccine development - 30/08/16

Doi : 10.1016/j.tube.2016.05.008

Thomas G. Evans ^a,^⁎ , Gavin J. Churchyard ^b,^c, Adam Penn-Nicholson ^d, Chen Chen ^e, Xu Gao ^f,^g, Dereck R. Tait ^h, Mark Hatherill ^d
^a Aeras, Rockville, MD, USA
^b Aurum Research Institute, Johannesburg, South Africa
^c School of Public Health, University of Witwatersrand, South Africa
^d South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa
^e Aeras, Beijing, China
^f Fudan University, Shanghai, China
^g Heidelberg University, Heidelberg, Germany
^h Aeras, Cape Town, South Africa

^∗Corresponding author. Aeras, 1405 Research Blvd, Rockville, MD 20850, USA.Aeras1405 Research BlvdRockvilleMD20850USA

Summary

The 4th Global Forum on TB Vaccines, convened in Shanghai, China, from 21 – 24 April 2015, brought together a wide and diverse community involved in tuberculosis vaccine research and development to discuss the current status of, and future directions for this critical effort. This paper summarizes the sessions on Developing TB Vaccines for Prevention of Disease, Prevention of Infection, and Immunotherapy Indications; Concepts and Approaches in Clinical Research & Development; and Epidemiological Research. Summaries of all sessions from the 4th Global Forum are compiled in a special supplement of Tuberculosis.

Le texte complet de cet article est disponible en PDF.

Keywords : Tuberculosis, Clinical trial, Epidemiology